New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
10:01 EDTM, FRX, DHI, INSM, CACI, LLL, WSM, DAN, ANGI, HAL, VAL, TS, STI, ALB, AZN, D, DD, JCP, JNJ, MCD, MPW, PSA, RVBD, AETOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aetna (AET) upgraded to Outperform from Neutral at Credit Suisse... Albemarle (ALB) upgraded to Buy from Neutral at BofA/Merrill... AstraZeneca (AZN) upgraded to Hold from Underperform at Jefferies... Dominion (D) upgraded to Buy from Neutral at UBS... DuPont (DD) upgraded to Buy from Neutral at BofA/Merrill... J.C. Penney (JCP) upgraded to Overweight from Neutral at Piper Jaffray... Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies... McDonald's (MCD) upgraded to Overweight from Equal Weight at Morgan Stanley... Medical Properties Trust (MPW) upgraded to Buy from Hold at Jefferies... Public Storage (PSA) upgraded to Buy from Hold at Jefferies... Riverbed (RVBD) upgraded to Hold from Sell at Deutsche Bank... SunTrust (STI) upgraded to Neutral from Underperform at BofA/Merrill... Valspar (VAL) upgraded to Outperform from Neutral at RW Baird... Tenaris (TS) upgraded to Outperform from Sector Perform at Howard Weil... Halliburton (HAL) upgraded to Outperform from Sector Perform at Howard Weil... Forest Labs (FRX) upgraded to Buy from Neutral at Buckingham... D.R. Horton (DHI) upgraded to Buy from Neutral at MKM Partners... Insmed (INSM) upgraded at JMP Securities... CACI International (CACI) upgraded to Overweight from Neutral at JPMorgan... L-3 Communications (LLL) upgraded to Neutral from Underweight at JPMorgan... H&R Block (HRB) upgraded to Buy from Neutral at BTIG... Williams-Sonoma (WSM) upgraded to Buy from Hold at Argus... Dana Holding (DAN) upgraded to Buy from Neutral at Goldman... Angie's List (ANGI) upgraded at Raymond James... Macy's (M) upgraded to Outperform from Market Perform at BMO Capital.
News For AET;ALB;AZN;D;DD;JCP;JNJ;MCD;MPW;PSA;RVBD;STI;TS;VAL;HAL;FRX;DHI;INSM;CACI;LLL;WSM;DAN;ANGI;M From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
October 13, 2014
12:05 EDTJCPJ.C. Penney risk/reward remains balanced, says RW Baird
Subscribe for More Information
10:12 EDTJCPHome Depot bench deep, Ellison departure not surprising, says RW Baird
RW Baird said it is not surprised to see Marvin Ellison leaving Home Depot (HD) since he was likely in the running for the CEO post that went to someone else, but the firm expects a smooth internal transition and noted that it views the company's management bench as deep. Baird, which maintains its Outperform rating on Home Depot, believes J.C. Penney (JCP) is getting a strong leader with extensive retail experience in hiring Ellison.
10:08 EDTJCP, DANOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
10:08 EDTDHI, AZN, LLLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:06 EDTJCP, MJ.C. Penney rises after selecting Home Depot executive as next CEO
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
08:52 EDTDHIUS Building Products & Homebuilding sector lowered at Barclays
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:38 EDTJCPJ.C. Penney names Marvin Ellison CEO-Designee
The board of J. C. Penney (JCP) announced the appointment of Marvin Ellison, currently executive vice president of stores at Home Depot (HD), as president and CEO-Designee, effective November 1. Ellison will also join the board. He will then succeed Myron E. Ullman, III as CEO of JCPenney on August 1, 2015. At that time, Ullman will become executive chairman of the board for a period of one year.
08:28 EDTLLLL-3 Communications upgraded to Fair Value from Sell at CRT Capital
Subscribe for More Information
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
07:42 EDTDANDana Holding downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTLLL, JNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
07:12 EDTRVBDRiverbed news already priced into stock, says JMP Securities
Subscribe for More Information
07:11 EDTDHID.R. Horton upgraded to Buy from Neutral at Compass Point
Subscribe for More Information
06:15 EDTM, JCPJ.C. Penney downgraded to Sell from Neutral at UBS
UBS downgraded its rating on J.C. Penney (JCP) shares to Sell saying the company's 2017 EBITDA target of $1.2B is overly optimistic as it assumes years of market share gains against strong competitors like Macy's (M) and Kohl's (KSS). UBS halved its price target for Penney shares to $5 from $10. The retailer's stock closed Friday down 52c to $7.12.
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use